<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Blood biomarkers for stroke</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Blood biomarkers for stroke</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Blood biomarkers for stroke</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Koto Ishida, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brett L Cucchiara, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H30408541"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This topic will discuss candidate blood biomarkers that may have a role in the evaluation and care of patients with stroke, as well as some of the more promising markers under investigation (<a class="graphic graphic_table graphicRef96469" href="/d/graphic/96469.html" rel="external">table 1</a>). Details about the clinical evaluation of stroke are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p><p>Specific blood biomarkers of autoimmune and hypercoagulable conditions relating to stroke are discussed separately. (See  <a class="medical medical_review" href="/d/html/1119.html" rel="external">"Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack", section on 'Hypercoagulable states'</a>.)</p><p class="headingAnchor" id="H757984989"><span class="h1">GENERAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>While measurement of blood markers of cardiac myocyte injury such as troponin has revolutionized the evaluation and management of patients with myocardial infarction, the role of blood biomarkers in stroke remains limited. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential roles in stroke evaluation</strong> – An ideal blood biomarker for stroke would be reliable, rapidly measured, and readily available. A suitable biomarker might assist with stroke diagnosis and determination of stroke subtype or mechanism, such as cardioembolism (see <a class="local">'Cardioembolic stroke'</a> below), large artery atherosclerosis (see <a class="local">'Large artery atherosclerosis'</a> below), and hypercoagulability (see <a class="local">'Hypercoagulability'</a> below) [<a href="#rid1">1</a>]. Other potential roles for stroke biomarkers include help in predicting response to acute therapy and in guiding specific primary and secondary prevention strategies (<a class="graphic graphic_table graphicRef96470" href="/d/graphic/96470.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Numerous biomarkers are associated with stroke outcome (see <a class="local">'Stroke outcome'</a> below), including the risk of first or recurrent stroke, though how to incorporate these markers into clinically meaningful prognostic tools remains controversial. Markers may also predict risk of early complications in stroke patients, allowing closer monitoring and earlier intervention. However, it remains uncertain how much additive value is provided beyond traditional risk assessment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges to biomarker development in stroke diagnosis</strong> – The development of diagnostic blood biomarkers for stroke, which might help distinguish stroke from mimics, faces tremendous challenges given the heterogeneity of stroke, the presence of the blood-brain-barrier, and the complexity of brain injury. Additionally, the optimal timing of measurement related to stroke is unknown, and significant variability across studies makes functional comparison challenging. To date, individual markers have lacked sufficient sensitivity and specificity for stroke diagnosis [<a href="#rid2">2,3</a>]. Panels of biomarkers may hold greater promise and are under active study, though they too have yet to demonstrate sufficient accuracy to be of clinical use [<a href="#rid4">4-9</a>].</p><p></p><p class="headingAnchor" id="H3927740109"><span class="h1">CANDIDATE BIOMARKERS</span><span class="headingEndMark"> — </span>A number of candidate biomarkers for stroke are listed in the table (<a class="graphic graphic_table graphicRef96469" href="/d/graphic/96469.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H2607067465"><span class="h2">Cardiac biomarkers</span><span class="headingEndMark"> — </span>Brain natriuretic peptide (BNP), also called B-type natriuretic peptide, is the main cardiac biomarker studied for its relationship with stroke. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>BNP</strong> – BNP is a neurohormone initially identified in the brain but released primarily from the heart. BNP is secreted from the cardiac ventricles in response to increased wall tension (myocyte stretch) or volume overload. Physiologically, BNP has diuretic, natriuretic, and hypotensive effects (see  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure", section on 'Physiologic role in HF'</a>). It increases urinary excretion of sodium, leading to expanded volume of urine, relaxes vascular smooth muscle, and inhibits both the sympathetic and renin-angiotensin-aldosterone systems. BNP is synthesized as a prohormone (proBNP), which is cleaved after release in the circulation into the biologically active C-terminal fragment and the inactive N-terminal (NT-proBNP) fragment. The half-life and stability of NT-proBNP is several times that of BNP, leading to generally higher concentrations of NT-proBNP.</p><p></p><p class="bulletIndent1">As discussed below, measurement of BNP in the setting of cryptogenic stroke is helpful to assess the likelihood of a cardioembolic source, including the presence of paroxysmal atrial fibrillation, although optimal cutoff values for individual assays are undefined. Substantially elevated BNP levels suggest the need for intensive cardiac evaluation, including echocardiography and prolonged cardiac rhythm monitoring. (See <a class="local">'Cardioembolic stroke'</a> below.)</p><p></p><p class="bulletIndent1">Plasma BNP or NT-proBNP is useful as a component of the evaluation of suspected heart failure when the diagnosis is uncertain. Details of BNP use in the cardiac setting are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a> and  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Natriuretic peptide'</a>.)</p><p></p><p class="headingAnchor" id="H2116945078"><span class="h2">Markers of stress response</span><span class="headingEndMark"> — </span>Biomarkers of stress response that have been studied for their association with stroke include copeptin and cortisol.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copeptin</strong> – Copeptin is a peptide consisting of the C-terminal part of pro-arginine vasopressin (AVP), which is released together with AVP from the pituitary in response to hemodynamic or osmotic stimuli. Copeptin has been associated with stroke risk and stroke outcome. (See <a class="local">'Copeptin and stroke risk'</a> below and <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cortisol</strong> – Acute physiologic stressors including stroke trigger activation of the hypothalamic-pituitary-adrenal axis and result in increased cortisol levels. Elevated cortisol level has been associated with stroke outcome. (See <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="headingAnchor" id="H3784132569"><span class="h2">Markers of atherogenesis/inflammation</span><span class="headingEndMark"> — </span>Markers of atherogenesis and/or inflammation include C-reactive protein (CRP), fatty acid–binding protein 4 (FABP4; also known as adipocyte protein AP2), lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>), mannose-binding lectin (MBL), and procalcitonin. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRP</strong> is an acute phase reactant predominantly produced by the liver and regulated by inflammatory cytokines. It generally increases in response to injury, infection, or inflammation, and has been studied extensively as a predictor of cardiovascular disease and an indicator of underlying systemic atherosclerosis. Standardized high-sensitivity assays (hs-CRP) are widely available. CRP elevation has been associated with stroke risk and large artery atherosclerosis. (See <a class="local">'CRP and stroke risk'</a> below and <a class="local">'Large artery atherosclerosis'</a> below.) </p><p></p><p class="bulletIndent1">The role of CRP in the estimation of cardiovascular risk and decision-making about statin therapy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1484.html" rel="external">"C-reactive protein in cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FABP4</strong> is a cytosolic lipid chaperone involved in regulating cellular lipid metabolism and lipid-induced endoplasmic reticulum stress in macrophages and the role of macrophages in atherosclerosis [<a href="#rid10">10</a>]. FABP4 elevation has been associated with stroke outcome. (See <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lp-PLA</strong><strong><sub>2</sub></strong> is an enzyme expressed predominantly by leukocytes that is involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators. It is a vascular-specific inflammatory biomarker highly expressed in the necrotic core of atherosclerotic plaque and is linked to plaque inflammation and instability. Both Lp-PLA<sub>2</sub> mass and activity can be measured in serum or plasma. Diagnostic testing for Lp-PLA<sub>2</sub> mass is available and used clinically for long-term cardiovascular risk prediction, though it is not commonly used in clinical practice for stroke evaluation. Although some studies suggest better reproducibility and reliability in vascular risk prediction over time compared with Lp-PLA<sub>2</sub> mass [<a href="#rid11">11,12</a>], the practical performance characteristics of the Lp-PLA<sub>2</sub> activity assay are less well-defined. Lp-PLA<sub>2</sub> elevation has been associated with stroke risk and large artery atherosclerosis. (See <a class="local">'Lp-PLA2 and stroke risk'</a> below and <a class="local">'Large artery atherosclerosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MBL</strong> is a recognition molecule that plays a role in innate immunity and is an activator of the complement pathway [<a href="#rid13">13</a>]. Interest in MBL has increased with evidence that the complement system is involved in the cascade of events, including coagulation, that are triggered by brain ischemia [<a href="#rid14">14</a>]. MBL has been associated with stroke outcome. (See <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procalcitonin</strong> is the precursor of calcitonin and is synthesized in various inflammatory states (eg, infection, shock, trauma, surgery, burn injury, chronic kidney disease), leading to its interest in stroke. Procalcitonin has been associated with stroke outcome. (See <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="bulletIndent1">Procalcitonin is best known for its role as a biomarker that helps distinguish bacterial infection from other causes of infection or inflammation. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections"</a>.)</p><p></p><p class="headingAnchor" id="H2181541228"><span class="h2">Markers of hemostasis</span><span class="headingEndMark"> — </span>Markers of hemostasis include D-dimer and fibrinogen.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-dimer</strong> is a fibrin degradation product generated during fibrinolysis, and levels are elevated in the setting of active clot formation and turnover. In clinical practice, D-dimer levels are incorporated into diagnostic algorithms used to identify patients with deep vein thrombosis and pulmonary embolism, and an elevated D-dimer level is supportive of the diagnosis of cerebral venous thrombosis. (See  <a class="medical medical_review" href="/d/html/1351.html" rel="external">"Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity", section on 'D-dimer'</a> and  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'D-dimer'</a>.) </p><p></p><p class="bulletIndent1">In addition, measurement of D-dimer in the setting of cryptogenic stroke may be helpful to assess the likelihood of cancer-related hypercoagulability, though optimal cutoff values for individual assays are undefined. (See <a class="local">'Hypercoagulability'</a> below.)</p><p></p><p class="bulletIndent1">Similarly, elevated D-dimer levels may identify patients with cryptogenic stroke potentially attributable to coronavirus disease 2019 (COVID-19) hypercoagulability. (See  <a class="medical medical_review" href="/d/html/128153.html" rel="external">"COVID-19: Neurologic complications and management of neurologic conditions", section on 'Cerebrovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinogen</strong> is the fundamental precursor to formation of the fibrin clot. Elevated fibrinogen levels have been shown to correlate with stroke risk, increased stroke severity, and poor outcome after stroke. A fibrinogen depletion coagulopathy may also play a role in hemorrhagic complications following use of intravenous thrombolytic therapy for acute ischemic stroke. (See <a class="local">'Fibrinogen and stroke risk'</a> below and <a class="local">'Intracerebral hemorrhage'</a> below and <a class="local">'Markers generally associated with stroke outcome'</a> below.)</p><p></p><p class="headingAnchor" id="H1558431441"><span class="h2">Markers of brain or vascular injury</span><span class="headingEndMark"> — </span>Markers of brain and or vascular injury include cellular fibronectin (c-Fn), glial fibrillary acidic protein (GFAP), matrix metalloproteinase 9 (MMP9), neuron-specific enolase (NSE), and S100 calcium binding protein B (S100B).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>c-FN</strong> is a glycoprotein primarily produced by endothelial cells, particularly vascular endothelium. Elevated c-FN<strong> </strong>levels have been associated with hemorrhagic transformation. (See <a class="local">'Intracerebral hemorrhage'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GFAP</strong> is predominantly produced by astrocytes, making it a potential brain-specific biomarker. It is released into the blood following stroke [<a href="#rid15">15</a>] and other types of brain injury. (See <a class="local">'Intracerebral hemorrhage'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMP9</strong> is a proteolytic enzyme that specifically degrades the major components of the basal lamina surrounding cerebral blood vessels. MMP9 elevation has been associated with intracerebral hemorrhage. (See <a class="local">'Intracerebral hemorrhage'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSE</strong>, an enzyme released after neuronal damage, has been studied as a marker for brain injury (see  <a class="medical medical_review" href="/d/html/4833.html" rel="external">"Hypoxic-ischemic brain injury in adults: Evaluation and prognosis", section on 'Biochemistry'</a>), including cerebral infarction. A systematic review of 12 studies including 597 patients concluded that measurement of NSE was of limited value for diagnosis of acute ischemic stroke, even though serum NSE levels were elevated in patients with stroke compared with controls, correlated with infarct volume, and correlated with the degree of neurologic deficit [<a href="#rid16">16</a>]. Major problems with NSE as a biomarker include delayed release into the systemic circulation after brain injury such that elevations occur too late to be clinically useful, and lack of specificity for cerebral infarction. As an example, a study of 72 patients with suspected stroke found that the sensitivity and specificity of NSE for the diagnosis of stroke was only 53 and 64 percent, respectively [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>S100B</strong> is an astroglial protein that has been studied as a serum marker for cerebral injury and disruption of the blood brain barrier. Small single-center studies have suggested S100B levels measured at multiple time points after stroke were predictive of a malignant course [<a href="#rid18">18</a>] and larger infarct volume and poor outcome [<a href="#rid19">19</a>]. It has also been investigated as an independent predictor of hemorrhagic deterioration after thrombolysis in ischemic stroke patients and as a diagnostic marker for stroke; in both of these scenarios, accuracy is too low to be clinically useful [<a href="#rid2">2,20</a>]. </p><p></p><p class="headingAnchor" id="H3380034142"><span class="h1">STROKE RISK</span></p><p class="headingAnchor" id="H1700431420"><span class="h2">BNP and stroke risk</span><span class="headingEndMark"> — </span>Elevated brain natriuretic peptide (BNP) levels have been associated with an increased risk of incident stroke. As examples, in data from a European consortium of population-based cohort studies, with more than 58,000 stroke-free participants followed for a median of approximately eight years, increasing levels of NT-proBNP were positively associated with the risk of ischemic and hemorrhagic stroke [<a href="#rid21">21</a>]. Subjects in the highest NT-proBNP quartile (NT-proBNP &gt;82.2 pg/mL) had twofold greater risk of stroke than those in the lowest quartile (NT-proBNP &lt;20.4 pg/mL), independent of other risk factors. In a subset of 1502 subjects in the population-based REGARDS study who had baseline NT-proBNP levels measured, those in the highest quartile of NT-proBNP levels had a nearly threefold increased risk of first stroke compared with those in the bottom quartile, even after adjusting for traditional vascular risk factors. Elevated BNP was particularly associated with cardioembolic stroke, with a ninefold greater risk for those in the top compared with the bottom quartile of NT-proBNP levels [<a href="#rid22">22</a>]. Another study of 381 patients admitted to a stroke unit with diagnosis of transient ischemic attack (TIA) reported that an NT-proBNP cut-off of &gt;800 pg/mL was independently associated with higher risk of stroke over a mean follow-up of 37 months. The risk was highest in the patients with cardioembolic TIA; however, the association also held to a lesser degree for TIA of undetermined source and for atherothrombotic TIA [<a href="#rid23">23</a>].</p><p>Elevated NT-proBNP levels appear to predict stroke risk even in patients with known atrial fibrillation treated with anticoagulation. In 6189 patients with available blood samples in the RE-LY trial, which randomized patients with atrial fibrillation to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, subjects with plasma NT-proBNP levels in the highest quartile (&gt;1402 ng/L) had an annual stroke risk of 2 percent, while those in the lowest quartile (&lt;387 ng/L) had an annual stroke risk of 0.8 percent [<a href="#rid24">24</a>]. NT-proBNP remained a predictor of stroke even after thromboembolic risk adjustment using the CHA<sub>2</sub>DS<sub>2</sub>-VASc risk model score (see  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'CHA2DS2-VASc score'</a>). Another study evaluated 14,892 patients with available blood samples from the ARISTOTLE trial, which randomized patients with atrial fibrillation to warfarin or <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>; subjects with NT-proBNP levels in the highest quartile (&gt;1250 ng/L) had an annual risk of stroke or systemic embolism of 2.2 percent, while those in the lowest quartile (≤363 ng/L) had an annual stroke risk of 0.7 percent [<a href="#rid25">25</a>]. Addition of NT-proBNP to the CHA<sub>2</sub>DS<sub>2</sub>-VASc score significantly improved prediction of embolic events.</p><p>While these data establish an increased risk of stroke associated with elevated BNP levels, it remains unclear how measurement of BNP might be incorporated into clinical practice, given that identified cut-off levels vary widely across studies. In addition, strategies for modifying treatment based on BNP levels in patients without a history of stroke have not been evaluated. However, it may be sensible to consider BNP levels in decision-making about use of oral anticoagulation for patients with otherwise low-risk atrial fibrillation.</p><p class="headingAnchor" id="H3171274537"><span class="h2">CRP and stroke risk</span><span class="headingEndMark"> — </span>Overall, available data do not suggest a clinically useful role of C-reactive protein (CRP) measurement in estimating future stroke risk for either first or recurrent stroke. A number studies have found an association between CRP and risk of first ischemic stroke in healthy adults [<a href="#rid11">11,26-34</a>], but this association is frequently attenuated after adjustment for traditional vascular risk factors, and the degree of absolute risk increase is small. As an example, a meta-analysis of 54 prospective longitudinal studies and individual records from over 160,000 patients without history of vascular disease demonstrated a significant association between CRP concentration and risk of first ischemic stroke [<a href="#rid34">34</a>]. Risk ratios per threefold higher CRP levels were 1.46 (95% CI 1.32-1.61) for ischemic stroke and 1.07 (95% CI 0.86-1.32) for hemorrhagic stroke. the association with ischemic stroke remained significant but attenuated after adjustment for conventional vascular risk factors.</p><p>The utility of CRP for predicting the risk of recurrent ischemic events after an initial transient ischemic attack or stroke is also unclear. One problem is that CRP levels increase acutely after stroke, raising uncertainty about the use of poststroke levels to predict long-term vascular risk [<a href="#rid35">35</a>]. Overall, there appears to be a modest correlation between CRP levels and recurrent stroke risk, though data are inconsistent.</p><p>In 6015 patients with prior stroke or transient ischemic attack in the PROGRESS study, CRP was associated with significantly increased risk of recurrent ischemic stroke after adjustment for other vascular risk factors [<a href="#rid36">36</a>]. The odds ratio comparing the highest tertile CRP with the lowest was 1.39 (95% CI 1.05-1.85). In 1244 patients with lacunar stroke in the SPS3 trial, those with levels the top quartile (hs-CRP &gt;4.86 mg/L) compared with the bottom quartile had a significantly higher risk of recurrent ischemic stroke (hazard ratio 2.54, 95% CI 1.30-4.96) even after adjustment for traditional risk factors [<a href="#rid37">37</a>]. In contrast, a report of 467 patients with prior ischemic stroke in the Northern Manhattan Stroke Study found no difference in risk of recurrent stroke for those in the highest quartile of hs-CRP compared with the lowest after adjustment for traditional vascular risk factors [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1904330474"><span class="h2">Fibrinogen and stroke risk</span><span class="headingEndMark"> — </span>Fibrinogen levels are associated with the risk of first stroke. In a meta-analysis of 31 prospective studies that included individual data from over 150,000 subjects without a prior history of stroke or cardiovascular disease, fibrinogen had a moderately strong association with risk of any stroke [<a href="#rid38">38</a>]. The hazard ratio for stroke was 2.06 for every 1 g/L increase in fibrinogen (95% CI 1.83-2.33), with only a modest attenuation of the effect after adjustment for other vascular risk factors. The relationship between fibrinogen and stroke risk was strongest in younger participants (age 40 to 59 years).</p><p>The association between fibrinogen and risk of recurrent stroke is less clear. In 472 patients with ischemic stroke included in a substudy of the PROGRESS trial, those in the top tertile of fibrinogen levels (&gt;4.04 g/L) compared with the bottom tertile (&lt;3.32 g/L) had a significantly increased recurrent stroke risk (odds ratio 1.34, 95% CI 1.01-1.78) [<a href="#rid36">36</a>]. However, in 817 subjects with ischemic stroke in the Edinburgh Stroke Study, no clear relationship between fibrinogen and risk of recurrent stroke was seen [<a href="#rid39">39</a>].</p><p>Overall, these data suggest that fibrinogen measurement might be used in moderate-risk patients with no history of stroke, particularly younger patients, to assist with decisions about whether to implement prevention strategies. However, there is no defined threshold level for fibrinogen, and the incremental additive value in improving risk reclassification has not been established. For patients with prior stroke, fibrinogen measurement is unlikely to impact treatment decisions.</p><p class="headingAnchor" id="H2368469477"><span class="h2">Lp-PLA2 and stroke risk</span><span class="headingEndMark"> — </span>A meta-analysis of 79,036 subjects in 32 prospective studies found that elevations in Lp-PLA<sub>2</sub> mass and activity were associated with an increased risk for ischemic stroke after adjustment for other predictors of vascular risk [<a href="#rid40">40</a>]. The association was strongest for Lp-PLA<sub>2</sub> mass; for each standard deviation increase in Lp-PLA<sub>2</sub> mass level, the risk of ischemic stroke increased 14 percent. In one population-based study, the risk of incident stroke was doubled in patients in the highest compared with lowest quartile of Lp-PLA<sub>2</sub> levels [<a href="#rid41">41</a>]. Another population-based longitudinal study with over 1900 participants and a median follow-up of 11 years found that the association between Lp-PLA<sub>2</sub> level and stroke risk varied by race and ethnicity; Lp-PLA<sub>2</sub> was associated with an increased risk of atherosclerotic stroke in non-Hispanic White subjects but not in Hispanic or Black subjects [<a href="#rid42">42</a>]. Further study is needed to determine if the relationship of Lp-PLA<sub>2</sub> and stroke risk differs according to race and ethnicity.</p><p>These data suggest the potential for using Lp-PLA<sub>2</sub> measurement to determine whether to implement primary prevention strategies, such as antiplatelet or statin therapy, in patients otherwise at intermediate risk of stroke where uncertainty about the benefit of these therapies exists. An Lp-PLA<sub>2</sub> mass level of 235 ng/mL has been suggested as a reasonable threshold for identifying those at increased cardiovascular risk [<a href="#rid43">43</a>]. However, measurement of Lp-PLA<sub>2</sub> is not appropriate in low-risk patients (ie, those with no or minimal vascular risk factors) or high-risk patients (ie, those with known cardiovascular disease risk factors, including prior stroke), as it would be unlikely to change management.</p><p>Elevated Lp-PLA<sub>2</sub> activity levels may predict short-term risk of recurrent cerebrovascular events, even after adjustment for clinical predictors [<a href="#rid44">44-47</a>]. However, Lp-PLA<sub>2</sub> measurement appears unlikely to impact treatment decisions for secondary prevention in patients with prior stroke; the change in risk assessment in this setting does not appear sufficient to alter management.</p><p class="headingAnchor" id="H4220072591"><span class="h2">Copeptin and stroke risk</span><span class="headingEndMark"> — </span>In a population-based study of over 1000 patients with ischemic stroke or TIA, increased copeptin was associated with recurrent cerebrovascular and other vascular events [<a href="#rid48">48</a>]. Another report of 100 patients admitted with TIA found that copeptin levels were higher in patients with recurrent cerebrovascular events [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H2192564080"><span class="h1">STROKE MECHANISM</span></p><p class="headingAnchor" id="H2469696981"><span class="h2">Cardioembolic stroke</span><span class="headingEndMark"> — </span>The strongest evidence for blood biomarkers linked with cardioembolic stroke supports an association with brain natriuretic peptide (BNP) and midregional pro-atrial natriuretic peptide (MR-proANP); lesser evidence suggests an association with D-dimer.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>BNP</strong> – Elevated plasma BNP levels are associated both with heart failure and with atrial fibrillation (AF) [<a href="#rid50">50</a>], two important cardioembolic stroke mechanisms with specific management implications. Measurement of BNP may thus help focus the stroke evaluation on the most likely etiologic mechanism. Identification of paroxysmal AF is a particular challenge, as detection rates of AF vary significantly based upon the monitoring strategy used. Paroxysmal AF, if transient, infrequent, and largely asymptomatic, may be undetected on standard cardiac monitoring such as continuous telemetry and 24- or 48-hour Holter monitors. More prolonged cardiac event monitoring (eg, for several weeks) can significantly increase the detection of AF in patients with transient ischemic attack or acute ischemic stroke (see  <a class="medical medical_review" href="/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Monitoring for subclinical atrial fibrillation'</a>). Measurement of BNP can be a useful adjunct to determining which patients are most likely to harbor occult AF.</p><p></p><p class="bulletIndent1">The association of elevated plasma BNP with cardioembolic stroke is supported by the results of several systematic reviews and meta-analyses [<a href="#rid51">51-53</a>]. In one of the larger individual studies, which evaluated 707 patients with acute ischemic stroke or transient ischemic attack, a plasma BNP &gt;76 pg/mL was an independent predictor of a cardioembolic mechanism (odds ratio 2.3, 95% CI 1.4-3.7) [<a href="#rid54">54</a>]. The sensitivity and specificity of BNP &gt;76 pg/mL for identification of a cardioembolic mechanism was 72 and 68 percent, respectively.</p><p></p><p class="bulletIndent1">Two studies evaluated NT-proBNP for identification of patients most likely to benefit from prolonged cardiac monitoring. In a study of 429 patients with ischemic stroke, including 103 with stroke attributed to AF, NT-proBNP ≥505 pg/mL had a sensitivity of 93 percent and specificity of 72 percent for identifying AF-related versus noncardioembolic stroke mechanism [<a href="#rid55">55</a>]. A study of 398 stroke patients from the Find-AF Randomized trial cohort with sinus rhythm on presenting EKG and no history of AF found that those with BNP ≥100 pg/mL benefited more from prolonged cardiac monitoring than those with BNP &lt;100 pg/mL with a number needed to screen of 3 versus 18, respectively [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1">Further evidence supporting BNP as a predictor of cardioembolic stroke comes from a post-hoc analysis of WARSS, a randomized trial that compared <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> in the prevention of recurrent ischemic stroke in patients with presumed noncardioembolic stroke. Among a cohort of 1028 patients in WARSS for whom blood samples were available, those with plasma NT-proBNP concentrations in the top 5 percent (&gt;750 pg/mL) had a significant reduction in the composite endpoint of stroke or death favoring warfarin (hazard ratio 0.30, 95% CI 0.12-0.84) [<a href="#rid57">57</a>]. In contrast, no benefit of warfarin over aspirin was seen in those with NT-proBNP levels ≤750 pg/mL. These findings suggest that elevated NT-proBNP concentrations identified a subgroup of patients with an occult cardioembolic stroke mechanism (eg, from atrial fibrillation or heart failure) who benefited from anticoagulation. However, WARSS was performed prior to widespread use of prolonged cardiac monitoring for acute stroke, and occult atrial fibrillation may have been underdiagnosed. </p><p></p><p class="bulletIndent1">Taken in its entirety, the data support a role for BNP as a predictor of cardioembolic stroke, particularly cardioembolism due to heart failure and atrial fibrillation. While various threshold levels have been identified in different studies, comparison across studies is difficult due to the use of different assays and variable measurement of BNP versus NT-proBNP. Nevertheless, it appears that the likelihood of cardioembolism rises linearly with BNP, such that markedly elevated levels in the setting of cryptogenic stroke should raise suspicion for a cardioembolic source with more aggressive diagnostic pursuit of heart failure and paroxysmal atrial fibrillation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>MR-proANP</strong> – Several reports have found that elevated levels of MR-proANP were associated with cardioembolic stroke and atrial fibrillation [<a href="#rid58">58-60</a>]. As an example, a study of over 1700 patients with acute ischemic stroke found that elevated levels of MR-proANP, collected within 24 hours of symptom onset, were associated with cardioembolic stroke and newly diagnosed atrial fibrillation [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-dimer</strong> – D-dimer is typically elevated in patients with stroke due to a cardioembolic source, though levels of elevation are usually more modest compared with cancer hypercoagulability. As an example, in a study of 707 prospectively evaluated patients with acute ischemic stroke, D-dimer levels were significantly higher in stroke classified as cardioembolic (1.1 mcg/mL) compared with stroke classified as atherothrombotic (0.5 mcg/mL), lacunar (0.6 mcg/mL), or undetermined (0.8 mcg/mL) [<a href="#rid54">54</a>]. Similar results have been seen in a number of other smaller studies [<a href="#rid61">61-64</a>]. Given this, the ability of D-dimer to discriminate between cardioembolic and non-cardioembolic stroke in individual patients is limited.</p><p></p><p class="headingAnchor" id="H2992742530"><span class="h2">Large artery atherosclerosis</span><span class="headingEndMark"> — </span>CRP and Lp-PLA<sub>2</sub> may be predictive of carotid artery and other large artery atherosclerosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRP</strong> – In a longitudinal study of 179 patients, CRP was an independent predictor for the development and rate of progression of early carotid atherosclerosis [<a href="#rid65">65</a>]. Progression intensified with increasing CRP levels even within the normal range, implicating a possible direct pro-inflammatory and prothrombotic vascular interaction. However, CRP concentration is more predictive of early carotid atherosclerotic activity and development than the extent of atherosclerosis or the degree of carotid stenosis [<a href="#rid65">65,66</a>]. Elevated CRP levels have not been shown to be useful as a diagnostic marker for identifying stroke or transient ischemic attack patients with significant carotid stenosis (&gt;50 percent) [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lp-PLA</strong><strong><sub>2</sub></strong> – A population-based longitudinal study with over 1900 participants and a median follow-up of 11 years found that Lp-PLA<sub>2</sub> mass levels were associated with stroke due to large artery atherosclerosis [<a href="#rid42">42</a>]. In two earlier studies evaluating patients with acute transient ischemic attack, each with approximately 165 patients, elevated Lp-PLA<sub>2</sub> activity was associated with a large artery atherosclerotic mechanism causing the cerebrovascular event [<a href="#rid44">44,45</a>]. However, the discriminatory value of Lp-PLA<sub>2</sub> measurement was not sufficient to allow its use as a diagnostic test for this purpose. </p><p></p><p class="headingAnchor" id="H46117414"><span class="h2">Cerebral venous thrombosis</span><span class="headingEndMark"> — </span>Similar to its role in deep vein thrombosis, D-dimer may be useful for evaluation of patients with suspected cerebral venous sinus thrombosis (CVT). This issue is discussed separately. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis", section on 'Laboratory tests'</a>.)</p><p class="headingAnchor" id="H990438033"><span class="h2">Hypercoagulability</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>With cancer</strong> – While relatively infrequent, cancer-associated hypercoagulability is an important stroke mechanism. Some experts, including one author of this topic, measure the D-dimer level routinely in patients with otherwise cryptogenic stroke and pursue aggressive diagnostic testing for occult malignancy in those with very elevated D-dimer levels.</p><p></p><p class="bulletIndent1">Although there is significant variability in D-dimer assays and specific cut-off values across studies [<a href="#rid67">67</a>], available data suggest that D-dimer elevation is useful for identifying patients at high-risk of having cancer hypercoagulability as a stroke mechanism [<a href="#rid68">68-76</a>]. As examples, in a report of 140 patients with ischemic stroke and active cancer, D-dimer levels were higher in patients with no identified cause of stroke aside from potential cancer hypercoagulability compared with those who had a determined, conventional stroke mechanism (8.4 versus 3.9 mcg/mL) [<a href="#rid68">68</a>]. In a case-control study of patients 204 with ischemic stroke, D-dimer levels were higher in 104 patients with active cancer compared with 100 patients with inactive cancer (5.7 versus 1.0 mcg/mL, versus 0.6 mcg/mL in 408 control patients with ischemic stroke but no history of cancer) [<a href="#rid69">69</a>]. In the active cancer group, elevated D-dimer levels were also associated with absence of a conventional stroke mechanism and the presence of multiple ischemic lesions in different vascular territories.</p><p></p><p class="bulletIndent1">In a retrospective report, the group of 71 patients with cryptogenic stroke and active cancer had significantly higher plasma D-dimer levels than the group of 277 patients with cryptogenic stroke without cancer or the control group of 33 patients with active cancer but no stroke (10.7 versus 0.5 versus 0.7 mcg/mL) [<a href="#rid70">70</a>]. Using a data-derived D-dimer cutoff of 2.15 mcg/mL, the sensitivity and specificity for identifying cancer hypercoagulability as the stroke mechanism was 74 and 97 percent, respectively. Among 10 patients without known active cancer who had multifocal lesions in different vascular territories and who exceeded the D-dimer cutoff, all had occult malignancy on further work-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>With COVID-19</strong> – The relationship of elevated D-dimer levels and hypercoagulability associated with COVID-19 as a potential stroke mechanism is discussed separately. (See  <a class="medical medical_review" href="/d/html/128153.html" rel="external">"COVID-19: Neurologic complications and management of neurologic conditions", section on 'Cerebrovascular disease'</a>.)</p><p></p><p class="headingAnchor" id="H1399323751"><span class="h2">Intracerebral hemorrhage</span><span class="headingEndMark"> — </span>Glial fibrillary acid protein (GFAP), cellular fibronectin (c-Fn), fibrinogen, and matrix metalloproteinase 9 (MMP9) levels have been associated with acute intracerebral hemorrhage or hemorrhagic transformation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GFAP </strong>– Acute intracerebral hemorrhage may cause sudden destruction of astroglial cells and an early increase in serum GFAP levels, whereas ischemic stroke results in a slower breakdown of astroglial cells and a delayed increase in GFAP levels [<a href="#rid77">77</a>]. Several studies and meta-analyses have demonstrated that GFAP levels are significantly higher in patients with intracerebral hemorrhage compared with ischemic stroke when measured in the acute period (two to six hours after symptom onset), suggesting a potential role in determining stroke subtype [<a href="#rid77">77-85</a>]. However, a number of factors may affect the diagnostic performance of GFAP, including specimen type, measurement method, hemorrhage location (lobar versus deep), hemorrhage volume, and population studied [<a href="#rid81">81,86</a>]. In addition, the sensitivity of GFAP for intracerebral hemorrhage is suboptimal compared with CT scan [<a href="#rid86">86</a>]. These obstacles hinder clinical use of GFAP in this scenario.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>c-FN</strong> – Prospective studies reported that high pretreatment cellular fibronectin (c-Fn) levels predicted the risk of hemorrhagic transformation after intravenous thrombolysis for acute ischemic stroke [<a href="#rid87">87,88</a>]. A 2020 systematic review identified several small studies suggesting that c-FN is associated with hemorrhagic transformation, severe brain edema, and poor functional outcome [<a href="#rid89">89</a>]. However, a rapid assay that could be used for decision making prior to thrombolysis is not clinically available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinogen</strong> – Fibrinogen levels decrease and fibrinogen degradation products (FDP) increase significantly within two hours of administration of intravenous thrombolysis for acute ischemic stroke [<a href="#rid90">90,91</a>]. This depletion of fibrinogen and subsequent formation of fibrinogen degradation products can cause an early fibrinogen degradation coagulopathy. While one report of 114 patients found that baseline pretreatment fibrinogen levels did not predict symptomatic intracerebral hemorrhage following intravenous thrombolysis for acute ischemic stroke [<a href="#rid92">92</a>], changes in fibrinogen and FDP may be predictive of hemorrhage.</p><p></p><p class="bulletIndent1">As examples, a study of 547 patients with acute ischemic stroke treated with intravenous rt-PA found that a ≥200 mg/dL decrease in fibrinogen over the first six hours after thrombolysis was associated with a fourfold increased risk of symptomatic intracerebral hemorrhage compared with a smaller decrease in fibrinogen [<a href="#rid93">93</a>]. In a similar cohort of 157 patients, an increase in fibrinogen degradation products &gt;200 mg/L at two hours after thrombolysis was associated with a nearly fivefold increase in the risk of early (within 24 hours) parenchymal intracerebral hemorrhage [<a href="#rid91">91</a>]. Early hematomas were significantly predictive of poor prognosis at three months.</p><p></p><p class="bulletIndent1">While these data suggest a potential role of serial fibrinogen measurement for assessing risk of post-thrombolysis hemorrhage, it is unclear how this might impact the decision to start intravenous thrombolysis treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMP9</strong> – In several small studies, MMP9 was an independent predictor of hemorrhagic transformation associated with acute ischemic stroke, both in patients treated with intravenous thrombolytic therapy [<a href="#rid88">88,94</a>] and in those not treated with thrombolysis [<a href="#rid95">95,96</a>].</p><p></p><p class="headingAnchor" id="H232970155"><span class="h1">STROKE OUTCOME</span><span class="headingEndMark"> — </span>A number of blood biomarkers have been evaluated for association with stroke outcome. While the strength of supporting evidence varies, none of the biomarkers is sufficiently validated for predicting outcome after stroke in routine clinical use.</p><p class="headingAnchor" id="H63772342"><span class="h2">Markers generally associated with stroke outcome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BNP</strong> – Elevated brain natriuretic peptide (BNP) levels are associated with increased poststroke mortality [<a href="#rid97">97</a>], although the incremental clinical utility of BNP measurement for predicting death after stroke is likely small. In a meta-analysis of individual data from 2258 patients with stroke, the addition of NT-proBNP to clinical variables resulted in a small improvement in prediction of mortality after stroke, reclassifying 8 percent of patients into more accurate risk categories [<a href="#rid98">98</a>]. Data on the association between BNP and functional outcome after stroke are inconsistent [<a href="#rid97">97,99,100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Copeptin</strong> – A systematic review published in 2021 found that copeptin levels were associated with poor outcome in all seven higher-quality studies where it was evaluated [<a href="#rid97">97</a>]. As an example, the multicenter CoRisk study evaluated 788 patients with acute ischemic stroke and measured copeptin levels within 24 hours of symptom onset [<a href="#rid101">101</a>]. The median copeptin levels for those with a favorable and unfavorable outcome were 9.6 and 32.2 pmol/L, respectively. A 10-fold increase in copeptin levels independently predicted unfavorable functional outcome (odds ratio 2.17, 95% CI 1.46-3.22) and mortality (hazard ratio 2.40, 95% CI 1.60-3.60) at 90 days, irrespective of acute treatment including thrombolysis. A risk reclassification analysis showed that copeptin significantly improved risk prediction beyond that achieved using the National Institutes of Health Stroke Scale (NIHSS) score and age. In a further refinement, the investigators derived and validated the CoRisk score, which incorporates four elements (treatment with or without thrombolysis, copeptin level, NIHSS score on admission, and age) to predict outcome at three months after ischemic stroke [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cortisol</strong> – In a 2021 systematic review, three of four higher-quality studies assessing cortisol found that higher levels were associated with poor outcome [<a href="#rid97">97</a>]. An earlier systematic review (2014) concluded that elevated cortisol levels after stroke were associated with morbidity and mortality, but the evidence was insufficient to determine if this association was independent of stroke severity [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>D-dimer</strong> – Early stroke progression or recurrence has been associated with increased thrombin generation and fibrin turnover, suggesting that D-dimer levels may help to identify patients at highest risk. D-dimer has been associated with poor stroke outcome in multiple studies [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FABP4</strong> – Fatty acid–binding protein 4 (FABP4) levels were associated with poor outcome in several higher-quality studies assessing FAB4 [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MBL</strong> – Two studies have found that elevated mannose-binding lectin (MBL) levels were associated with poor outcome [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procalcitonin</strong> – Three high-quality studies have found that increased procalcitonin levels were associated with poor outcome [<a href="#rid97">97</a>]. </p><p></p><p class="headingAnchor" id="H1141006009"><span class="h2">Markers inconsistently associated with stroke outcome</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CRP</strong> – The association of C-reactive protein (CRP) levels and outcome has been inconsistent across multiple studies [<a href="#rid97">97</a>]. Given these results, measurement of CRP for prediction of stroke outcome is not recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrinogen</strong> – Fibrinogen levels have been associated with poor outcome after stroke in some reports [<a href="#rid90">90,91,104,105</a>]; however, higher-quality studies have not confirmed this association [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMP9</strong> – The evidence for MMP9 in stroke outcome is inconsistent [<a href="#rid89">89,97</a>]. A 2020 systematic review of cohort or case-control studies with computed tomographic or magnetic resonance imaging and functional outcome data at three months after stroke onset identified 11 studies with over 5000 patients and found no association of MMP9 levels with outcome [<a href="#rid89">89</a>]. There was a very high level of heterogeneity among the included studies, which lowers the reliability of the results.</p><p></p><p class="headingAnchor" id="H30408705"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Ideal blood biomarkers for stroke would be reliable, rapidly measured, and readily available, and might assist with diagnosis, determination of stroke subtype or mechanism, or prediction of outcome or response to therapy (<a class="graphic graphic_table graphicRef96470" href="/d/graphic/96470.html" rel="external">table 2</a>). Numerous biomarkers and panels of biomarkers have been studied to improve the early diagnosis of stroke, but none have sufficient sensitivity or specificity for routine clinical use. Several biomarkers are associated with stroke outcome, but it remains uncertain how much additive value is provided beyond traditional risk assessment. Two biomarkers, NT-proBNP and D-dimer, may have the strongest data to support clinical use in differentiating stroke mechanism in particular. (See <a class="local">'General considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Candidate biomarkers for stroke diagnosis (<a class="graphic graphic_table graphicRef96469" href="/d/graphic/96469.html" rel="external">table 1</a>) include the following, though none have shown sufficient sensitivity or specificity to be clinically useful:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brain natriuretic peptide (BNP) (see <a class="local">'Cardiac biomarkers'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Copeptin and cortisol (see <a class="local">'Markers of stress response'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>C-reactive protein (CRP), fatty acid–binding protein 4 (FABP4), lipoprotein-associated phospholipase A2 (Lp-PLA<sub>2</sub>), mannose-binding lectin (MBL), and procalcitonin (see <a class="local">'Markers of atherogenesis/inflammation'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>D-dimer and fibrinogen (see <a class="local">'Markers of hemostasis'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cellular fibronectin (c-Fn), glial fibrillary acidic protein (GFAP), matrix metalloproteinase 9 (MMP9), neuron-specific enolase (NSE), and S100 calcium binding protein B (S100B) (see <a class="local">'Markers of brain or vascular injury'</a> above) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of BNP, CRP, fibrinogen, and Lp-PLA<sub>2</sub> have been associated with an increased risk of stroke. (See <a class="local">'Stroke risk'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of some biomarkers have been associated with specific stroke mechanisms or complications, including BNP (cardioembolic stroke), CRP and Lp-PLA<sub>2</sub> (large artery atherosclerosis), D-dimer (cerebral venous thrombosis and hypercoagulability), and GFAP, c-FN, fibrinogen, and MMP9 (intracerebral hemorrhage or hemorrhagic transformation). (See <a class="local">'Stroke mechanism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant elevations in NT-proBNP may be clinically useful in targeting prolonged cardiac monitoring for those patients with cryptogenic embolic stroke most likely to have undetected paroxysmal atrial fibrillation and in targeting echocardiography at those most likely to have underlying severe heart failure as the stroke mechanism. (See <a class="local">'Cardioembolic stroke'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very elevated levels of D-dimer in patients with cryptogenic stroke should raise suspicion of occult malignancy causing cancer hypercoagulability and prompt thorough cancer screening. Elevated D-dimer levels in patients with cryptogenic stroke and COVID-19 may also suggest hypercoagulability as a possible stroke mechanism. (See <a class="local">'Hypercoagulability'</a> above and  <a class="medical medical_review" href="/d/html/128153.html" rel="external">"COVID-19: Neurologic complications and management of neurologic conditions", section on 'Cerebrovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biomarkers with the best evidence of an association with stroke outcome include BNP, copeptin, cortisol, D-dimer, FABP4, MBL, and procalcitonin. However, none is sufficiently validated for routine clinical use. (See <a class="local">'Stroke outcome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119:2408.</a></li><li><a class="nounderline abstract_t">Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 2008; 39:2902.</a></li><li><a class="nounderline abstract_t">Bustamante A, López-Cancio E, Pich S, et al. Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study. Stroke 2017; 48:2419.</a></li><li><a class="nounderline abstract_t">Laskowitz DT, Blessing R, Floyd J, et al. Panel of biomarkers predicts stroke. Ann N Y Acad Sci 2005; 1053:30.</a></li><li><a class="nounderline abstract_t">Laskowitz DT, Kasner SE, Saver J, et al. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009; 40:77.</a></li><li><a class="nounderline abstract_t">Lynch JR, Blessing R, White WD, et al. Novel diagnostic test for acute stroke. Stroke 2004; 35:57.</a></li><li><a class="nounderline abstract_t">An SA, Kim J, Kim OJ, et al. Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke. Clin Biochem 2013; 46:710.</a></li><li><a class="nounderline abstract_t">Knauer C, Knauer K, Müller S, et al. A biochemical marker panel in MRI-proven hyperacute ischemic stroke-a prospective study. BMC Neurol 2012; 12:14.</a></li><li><a class="nounderline abstract_t">Bustamante A, Penalba A, Orset C, et al. Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes. Neurology 2021; 96:e1928.</a></li><li><a class="nounderline abstract_t">Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009; 15:1383.</a></li><li><a class="nounderline abstract_t">Elkind MS, Tai W, Coates K, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166:2073.</a></li><li><a class="nounderline abstract_t">Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 2010; 122:2183.</a></li><li><a class="nounderline abstract_t">Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40:423.</a></li><li><a class="nounderline abstract_t">Fumagalli S, De Simoni MG. Lectin Complement Pathway and Its Bloody Interactions in Brain Ischemia. Stroke 2016; 47:3067.</a></li><li><a class="nounderline abstract_t">Wunderlich MT, Wallesch CW, Goertler M. Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur J Neurol 2006; 13:1118.</a></li><li><a class="nounderline abstract_t">Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis 2005; 20:213.</a></li><li><a class="nounderline abstract_t">González-García S, González-Quevedo A, Peña-Sánchez M, et al. Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke. J R Coll Physicians Edinb 2012; 42:199.</a></li><li><a class="nounderline abstract_t">Foerch C, Otto B, Singer OC, et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004; 35:2160.</a></li><li><a class="nounderline abstract_t">Foerch C, Singer OC, Neumann-Haefelin T, et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005; 62:1130.</a></li><li><a class="nounderline abstract_t">Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38:2491.</a></li><li><a class="nounderline abstract_t">Di Castelnuovo A, Veronesi G, Costanzo S, et al. NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke. Stroke 2019; 50:610.</a></li><li><a class="nounderline abstract_t">Cushman M, Judd SE, Howard VJ, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke 2014; 45:1646.</a></li><li><a class="nounderline abstract_t">Rodríguez-Castro E, Hervella P, López-Dequidt I, et al. NT-pro-BNP: A novel predictor of stroke risk after transient ischemic attack. Int J Cardiol 2020; 298:93.</a></li><li><a class="nounderline abstract_t">Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125:1605.</a></li><li><a class="nounderline abstract_t">Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61:2274.</a></li><li><a class="nounderline abstract_t">Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000; 20:1052.</a></li><li><a class="nounderline abstract_t">Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.</a></li><li><a class="nounderline abstract_t">Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32:2575.</a></li><li><a class="nounderline abstract_t">Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003; 108:166.</a></li><li><a class="nounderline abstract_t">Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107:2016.</a></li><li><a class="nounderline abstract_t">Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557.</a></li><li><a class="nounderline abstract_t">Bos MJ, Schipper CM, Koudstaal PJ, et al. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation 2006; 114:1591.</a></li><li><a class="nounderline abstract_t">Elkind MS, Luna JM, Moon YP, et al. High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study. Neurology 2009; 73:1300.</a></li><li><a class="nounderline abstract_t">Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375:132.</a></li><li><a class="nounderline abstract_t">Elkind MS, Leon V, Moon YP, et al. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke 2009; 40:3233.</a></li><li><a class="nounderline abstract_t">Woodward M, Lowe GD, Campbell DJ, et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36:2143.</a></li><li><a class="nounderline abstract_t">Elkind MS, Luna JM, McClure LA, et al. C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. Stroke 2014; 45:707.</a></li><li><a class="nounderline abstract_t">Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294:1799.</a></li><li><a class="nounderline abstract_t">Whiteley W, Jackson C, Lewis S, et al. Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study. Stroke 2011; 42:10.</a></li><li><a class="nounderline abstract_t">Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536.</a></li><li><a class="nounderline abstract_t">Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111:570.</a></li><li><a class="nounderline abstract_t">Katan M, Moon YP, Paik MC, et al. Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study. PLoS One 2014; 9:e83393.</a></li><li><a class="nounderline abstract_t">Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006; 9:138.</a></li><li><a class="nounderline abstract_t">Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009; 40:2332.</a></li><li><a class="nounderline abstract_t">Delgado P, Chacón P, Penalba A, et al. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients. Cerebrovasc Dis 2012; 33:150.</a></li><li><a class="nounderline abstract_t">Elkind MS, Tai W, Coates K, et al. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009; 27:42.</a></li><li><a class="nounderline abstract_t">Lin J, Zheng H, Cucchiara BL, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology 2015; 85:1585.</a></li><li><a class="nounderline abstract_t">Greisenegger S, Segal HC, Burgess AI, et al. Copeptin and Long-Term Risk of Recurrent Vascular Events After Transient Ischemic Attack and Ischemic Stroke: Population-Based Study. Stroke 2015; 46:3117.</a></li><li><a class="nounderline abstract_t">Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011; 76:563.</a></li><li><a class="nounderline abstract_t">Cameron A, Cheng HK, Lee RP, et al. Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis. Neurology 2021; 97:e1775.</a></li><li><a class="nounderline abstract_t">Llombart V, Antolin-Fontes A, Bustamante A, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. Stroke 2015; 46:1187.</a></li><li><a class="nounderline abstract_t">Bai J, Sun H, Xie L, et al. Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis. Int J Neurosci 2018; 128:1100.</a></li><li><a class="nounderline abstract_t">Pathak A, Pandey SP, Madhukar P, et al. Blood Biomarkers for the Differentiation of Cardiac Ischemic Stroke Subtypes: A Systematic Review. Cardiovasc Hematol Disord Drug Targets 2019; 19:215.</a></li><li><a class="nounderline abstract_t">Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 2008; 39:2280.</a></li><li><a class="nounderline abstract_t">Kneihsl M, Gattringer T, Bisping E, et al. Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke. Stroke 2019; 50:2223.</a></li><li><a class="nounderline abstract_t">Wasser K, Weber-Krüger M, Gröschel S, et al. Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial. Stroke 2020; 51:395.</a></li><li><a class="nounderline abstract_t">Longstreth WT Jr, Kronmal RA, Thompson JL, et al. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 2013; 44:714.</a></li><li><a class="nounderline abstract_t">Katan M, Fluri F, Schuetz P, et al. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010; 56:1045.</a></li><li><a class="nounderline abstract_t">Schweizer J, Arnold M, König IR, et al. Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke. J Am Coll Cardiol 2022; 79:1369.</a></li><li><a class="nounderline abstract_t">De Marchis GM, Schneider J, Weck A, et al. Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke. Neurology 2018; 90:e455.</a></li><li><a class="nounderline abstract_t">Isenegger J, Meier N, Lämmle B, et al. D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis 2010; 29:82.</a></li><li><a class="nounderline abstract_t">Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry 2011; 82:986.</a></li><li><a class="nounderline abstract_t">Ageno W, Finazzi S, Steidl L, et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch Intern Med 2002; 162:2589.</a></li><li><a class="nounderline abstract_t">Wiseman S, Marlborough F, Doubal F, et al. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis 2014; 37:64.</a></li><li><a class="nounderline abstract_t">Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation 2001; 104:63.</a></li><li><a class="nounderline abstract_t">Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol 1997; 17:2167.</a></li><li><a class="nounderline abstract_t">Johnson ED, Schell JC, Rodgers GM. The D-dimer assay. Am J Hematol 2019; 94:833.</a></li><li><a class="nounderline abstract_t">Schwarzbach CJ, Schaefer A, Ebert A, et al. Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology. Stroke 2012; 43:3029.</a></li><li><a class="nounderline abstract_t">Lee EJ, Nah HW, Kwon JY, et al. Ischemic stroke in patients with cancer: is it different from usual strokes? Int J Stroke 2014; 9:406.</a></li><li><a class="nounderline abstract_t">Kim SJ, Park JH, Lee MJ, et al. Clues to occult cancer in patients with ischemic stroke. PLoS One 2012; 7:e44959.</a></li><li><a class="nounderline abstract_t">Seok JM, Kim SG, Kim JW, et al. Coagulopathy and embolic signal in cancer patients with ischemic stroke. Ann Neurol 2010; 68:213.</a></li><li><a class="nounderline abstract_t">Dardiotis E, Aloizou AM, Markoula S, et al. Cancer-associated stroke: Pathophysiology, detection and management (Review). Int J Oncol 2019; 54:779.</a></li><li><a class="nounderline abstract_t">Xie X, Chen L, Zeng J, et al. Clinical features and biological markers of lung cancer-associated stroke. J Int Med Res 2016; 44:1483.</a></li><li><a class="nounderline abstract_t">Selvik HA, Thomassen L, Bjerkreim AT, Næss H. Cancer-Associated Stroke: The Bergen NORSTROKE Study. Cerebrovasc Dis Extra 2015; 5:107.</a></li><li><a class="nounderline abstract_t">Kono T, Ohtsuki T, Hosomi N, et al. Cancer-associated ischemic stroke is associated with elevated D-dimer and fibrin degradation product levels in acute ischemic stroke with advanced cancer. Geriatr Gerontol Int 2012; 12:468.</a></li><li><a class="nounderline abstract_t">Shen Y, Li Y, Chen C, et al. D-dimer and diffusion-weighted imaging pattern as two diagnostic indicators for cancer-related stroke: A case-control study based on the STROBE guidelines. Medicine (Baltimore) 2020; 99:e18779.</a></li><li><a class="nounderline abstract_t">Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006; 77:181.</a></li><li><a class="nounderline abstract_t">Perry LA, Lucarelli T, Penny-Dimri JC, et al. Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. Int J Stroke 2019; 14:390.</a></li><li><a class="nounderline abstract_t">Kumar A, Misra S, Yadav AK, et al. Role of glial fibrillary acidic protein as a biomarker in differentiating intracerebral haemorrhage from ischaemic stroke and stroke mimics: a meta-analysis. Biomarkers 2020; 25:1.</a></li><li><a class="nounderline abstract_t">Cabezas JA, Bustamante A, Giannini N, et al. Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis. J Investig Med 2020; 68:1379.</a></li><li><a class="nounderline abstract_t">Luger S, Witsch J, Dietz A, et al. Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke. Clin Chem 2017; 63:377.</a></li><li><a class="nounderline abstract_t">Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis 2009; 27:37.</a></li><li><a class="nounderline abstract_t">Undén J, Strandberg K, Malm J, et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation. J Neurol 2009; 256:72.</a></li><li><a class="nounderline abstract_t">Foerch C, Niessner M, Back T, et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem 2012; 58:237.</a></li><li><a class="nounderline abstract_t">Katsanos AH, Makris K, Stefani D, et al. Plasma Glial Fibrillary Acidic Protein in the Differential Diagnosis of Intracerebral Hemorrhage. Stroke 2017; 48:2586.</a></li><li><a class="nounderline abstract_t">Kamtchum-Tatuene J, Jickling GC. Blood Biomarkers for Stroke Diagnosis and Management. Neuromolecular Med 2019; 21:344.</a></li><li><a class="nounderline abstract_t">Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004; 35:1671.</a></li><li><a class="nounderline abstract_t">Castellanos M, Sobrino T, Millán M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007; 38:1855.</a></li><li><a class="nounderline abstract_t">Wang L, Deng L, Yuan R, et al. Association of Matrix Metalloproteinase 9 and Cellular Fibronectin and Outcome in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Front Neurol 2020; 11:523506.</a></li><li><a class="nounderline abstract_t">Tanne D, Macko RF, Lin Y, et al. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 2006; 37:1798.</a></li><li><a class="nounderline abstract_t">Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke 2004; 35:1323.</a></li><li><a class="nounderline abstract_t">Cocho D, Borrell M, Martí-Fàbregas J, et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006; 37:996.</a></li><li><a class="nounderline abstract_t">Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology 2013; 80:1216.</a></li><li><a class="nounderline abstract_t">Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107:598.</a></li><li><a class="nounderline abstract_t">Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34:40.</a></li><li><a class="nounderline abstract_t">Montaner J, Alvarez-Sabín J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32:1759.</a></li><li><a class="nounderline abstract_t">Montellano FA, Ungethüm K, Ramiro L, et al. Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis: A Systematic Review. Stroke 2021; 52:543.</a></li><li><a class="nounderline abstract_t">García-Berrocoso T, Giralt D, Bustamante A, et al. B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis. Neurology 2013; 81:1976.</a></li><li><a class="nounderline abstract_t">Rost NS, Biffi A, Cloonan L, et al. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke 2012; 43:441.</a></li><li><a class="nounderline abstract_t">Whiteley W, Wardlaw J, Dennis M, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012; 43:86.</a></li><li><a class="nounderline abstract_t">De Marchis GM, Katan M, Weck A, et al. Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study. Neurology 2013; 80:1278.</a></li><li><a class="nounderline abstract_t">De Marchis GM, Dankowski T, König IR, et al. A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. Neurology 2019; 92:e1517.</a></li><li><a class="nounderline abstract_t">Barugh AJ, Gray P, Shenkin SD, et al. Cortisol levels and the severity and outcomes of acute stroke: a systematic review. J Neurol 2014; 261:533.</a></li><li><a class="nounderline abstract_t">Turaj W, Słowik A, Dziedzic T, et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 2006; 246:13.</a></li><li><a class="nounderline abstract_t">del Zoppo GJ, Levy DE, Wasiewski WW, et al. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009; 40:1687.</a></li></ol></div><div id="topicVersionRevision">Topic 96239 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364974" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18658039" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Blood biomarkers in the diagnosis of ischemic stroke: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28716979" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179504" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Panel of biomarkers predicts stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18948614" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671250" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Novel diagnostic test for acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462697" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22400994" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A biochemical marker panel in MRI-proven hyperacute ischemic stroke-a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33674361" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19966778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060536" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21098459" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lipoprotein-associated and secreted phospholipases A₂in cardiovascular disease: roles as biological effectors and biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14568388" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of mannose-binding lectin in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27811336" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lectin Complement Pathway and Its Bloody Interactions in Brain Ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987165" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Release of glial fibrillary acidic protein is related to the neurovascular status in acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123539" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22953311" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum neuron-specific enolase and S100 calcium binding protein B biomarker levels do not improve diagnosis of acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15297628" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009772" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673718" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786848" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24757103" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31272739" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : NT-pro-BNP: A novel predictor of stroke risk after transient ischemic attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22374183" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23563134" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764672" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10733371" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692019" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821545" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12681999" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : C-reactive protein and the future risk of thromboembolic stroke in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12432042" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17015791" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841382" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-sensitivity C-reactive protein predicts mortality but not stroke: the Northern Manhattan Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031199" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644070" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16151030" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Associations of inflammatory and hemostatic variables with the risk of recurrent stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24523037" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16219884" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21127302" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435228" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699277" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24416164" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849876" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19461040" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22178747" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018137" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26311748" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26451023" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Copeptin and Long-Term Risk of Recurrent Vascular Events After Transient Ischemic Attack and Ischemic Stroke: Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228295" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Stress hormones predict cerebrovascular re-events after transient ischemic attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34504030" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Biomarkers for Atrial Fibrillation Detection After Stroke: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765726" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29874952" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Detection of cardioembolic stroke with B-type natriuretic peptide or N-terminal pro-BNP: a comparative diagnostic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30160220" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Blood Biomarkers for the Differentiation of Cardiac Ischemic Stroke Subtypes: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535284" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31216968" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Blood Biomarkers of Heart Failure and Hypercoagulation to Identify Atrial Fibrillation-Related Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31813354" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Brain Natriuretic Peptide and Discovery of Atrial Fibrillation After Stroke: A Subanalysis of the Find-AFRANDOMISED Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23339958" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20846604" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35393018" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321236" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Midregional proatrial natriuretic peptide improves risk stratification after ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19907168" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : D-dimers predict stroke subtype when assessed early.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296900" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12456231" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401164" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11435339" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351386" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30945756" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The D-dimer assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22996958" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23981525" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Ischemic stroke in patients with cancer: is it different from usual strokes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22984594" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Clues to occult cancer in patients with ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695014" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Coagulopathy and embolic signal in cancer patients with ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30628661" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cancer-associated stroke: Pathophysiology, detection and management (Review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28322105" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical features and biological markers of lung cancer-associated stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26648966" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cancer-Associated Stroke: The Bergen NORSTROKE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22233138" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Cancer-associated ischemic stroke is associated with elevated D-dimer and fibrin degradation product levels in acute ischemic stroke with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977868" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : D-dimer and diffusion-weighted imaging pattern as two diagnostic indicators for cancer-related stroke: A case-control study based on the STROBE guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174653" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303809" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31702405" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Role of glial fibrillary acidic protein as a biomarker in differentiating intracerebral haemorrhage from ischaemic stroke and stroke mimics: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32907910" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27881450" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018136" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19221847" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22125303" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28751552" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Plasma Glial Fibrillary Acidic Protein in the Differential Diagnosis of Intracerebral Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30830566" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Blood Biomarkers for Stroke Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166391" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478737" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33329294" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Association of Matrix Metalloproteinase 9 and Cellular Fibronectin and Outcome in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763191" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15105521" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497981" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23486872" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566373" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12511748" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11486102" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33430636" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24186915" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116811" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Brain natriuretic peptide predicts functional outcome in ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22020034" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468541" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Copeptin adds prognostic information after ischemic stroke: results from the CoRisk study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30824558" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477489" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cortisol levels and the severity and outcomes of acute stroke: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650435" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299642" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hyperfibrinogenemia and functional outcome from acute ischemic stroke.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
